Y-mAbs Reports 14% Revenue Decline and $3.2 Million Net Loss in Q2 2025

Y-mAbs Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a decline in revenue and a continued net loss. The company generated total revenues of $19.5 million for the three months ended June 30, 2025, a decrease of 14% compared to $22.8 million in the same period last year. This decline was primarily driven by a 17% drop in net product revenue from its FDA-approved drug DANYELZA, which amounted to $19.0 million, down from $22.8 million in the prior year. The decrease in revenue was attributed to reduced patient volume and competition, particularly in the U.S. market, where sales fell to $14.3 million from $15.2 million.

In terms of profitability, Y-mAbs reported a net loss of $3.2 million for the second quarter, significantly improved from a net loss of $9.2 million in the same quarter of 2024. The company’s operating costs also decreased, with total operating expenses falling by 24% to $22.5 million, driven by reductions in selling, general, and administrative expenses, which dropped by 34% to $11.3 million. Research and development expenses also saw a decline of 10% to $11.1 million, reflecting the company's ongoing efforts to streamline operations following a business realignment announced in January 2025.

Y-mAbs continues to focus on its strategic initiatives, including the ongoing commercialization of DANYELZA and the development of its SADA PRIT technology platform. The company is currently engaged in multiple clinical trials for DANYELZA, including a post-approval commitment study and trials for additional indications. The company also reported a significant increase in royalty revenue from distribution partners, totaling $1.9 million for the quarter, compared to $2.8 million in the previous year.

As of June 30, 2025, Y-mAbs had cash and cash equivalents of $62.3 million, down from $67.2 million at the end of 2024. The company anticipates that its current cash reserves will be sufficient to fund operations through at least 2028, assuming no significant changes in its business plan. However, the company is also navigating the complexities of a pending merger with Perseus BidCo US, Inc., which could impact its operational flexibility and financial strategies. The merger agreement, announced on August 4, 2025, includes a cash tender offer for the company's outstanding shares, with a purchase price of $8.60 per share.

Looking ahead, Y-mAbs remains focused on advancing its clinical programs and exploring additional partnerships to enhance its product pipeline. The company acknowledges the inherent risks and uncertainties associated with drug development and market acceptance, which could affect its financial performance and operational plans in the future.